The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
Open accessAbstract
BACKGROUND: No proven effective medical therapy for surgery and radiation-refractory meningiomas exists. Sunitinib malate (SU011248) is a small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor, abundant in meningiomas. METHODS: This was a prospective, multicenter, investigator-initiated single-arm phase II trial. The primary cohort enrolled patients with surgery and radiation-refractory recurrent World Health Organization (WHO) grades II-III meningioma. An exploratory cohort enrolled patients with WHO grade I meningioma, hemangiopericytoma, or hemangioblastoma. Sunitinib was administered at 50 mg/d for days 1-28 of every 42-day cycle. The primary endpoint was the rate of 6-month progression-free survival (PFS6), with secondary endpoints of radiographic response rate, safety, PFS, and overall survival. Exploratory objectives include analysis of tumoral molecular markers and MR perfusion imaging. RESULTS: Thirty-six patients with high-grade meningioma (30 atypical and 6 anaplastic) were enrolled. Patients were heavily pretreated (median number of 5 recurrences, range 2-10). PFS6 rate was 42%, meeting the primary endpoint. Median PFS was 5.2 months (95% CI: 2.8-8.3 mo), and median overall survival was 24.6 months (95% CI: 16.5-38.4 mo). Thirteen patients enrolled in the exploratory cohort. Overall toxicity included 1 grade 5 intratumoral hemorrhage, 2 grade 3 and 1 grade 4 CNS/intratumoral hemorrhages, 1 grade 3 and 1 grade 4 thrombotic microangiopathy, and 1 grade 3 gastrointestinal perforation. Expression of VEGFR2 predicted PFS of a median of 1.4 months in VEGFR2-negative patients versus 6.4 months in VEGFR2-positive patients (P = .005). CONCLUSION: Sunitinib is active in recurrent atypical/malignant meningioma patients. A randomized trial should be performed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Self-citationResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 2,157
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Robinson, D. R., Wu, Y.-M., Kalyana-Sundaram, S., Cao, X., Lonigro, R. J., Sung, Y.-S., Chen, C.-L., Zhang, L., Wang, R., Su, F., et al. (2013) · Nature Genetics · doi:10.1038/ng.2509 · Cited by 837
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors
Chmielecki, J., Crago, A. M., Rosenberg, M., O'Connor, R., Walker, S. R., Ambrogio, L., Auclair, D., McKenna, A., Heinrich, M. C., Frank, D. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2522 · Cited by 606
PDGF receptors as cancer drug targets
Pietras, K., Sjöblom, T., Rubin, K., Heldin, C.-H., & Östman, A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00089-8 · Cited by 465
Schweizer, L., Koelsche, C., Sahm, F., Piro, R. M., Capper, D., Reuss, D. E., Pusch, S., Habel, A., Meyer, J., Göck, T., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1117-6 · Cited by 389
Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone
Grunberg, S. M., Weiss, M. H., Spitz, I. M., Ahmadi, J., Sadun, A., Russell, C. A., Lucci, L., & Stevenson, L. L. (1991) · Journal of Neurosurgery · doi:10.3171/jns.1991.74.6.0861 · Cited by 379
Machein, M. R., & Plate, K. H. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006416003964 · Cited by 236
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series
Lou, E., Sumrall, A. L., Turner, S., Peters, K. B., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Herndon, J. E., McSherry, F., Norfleet, J., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0861-0 · Cited by 196
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
Norden, A. D., Raizer, J. J., Abrey, L. E., Lamborn, K. R., Lassman, A. B., Chang, S. M., Yung, W. K. A., Gilbert, M. R., Fine, H. A., Mehta, M., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9948-7 · Cited by 196
Self-citationTemozolomide for treatment-resistant recurrent meningioma
Chamberlain, M. C., Tsao-Wei, D. D., & Groshen, S. (2004) · Neurology · doi:10.1212/01.wnl.0000118300.82017.f4 · Cited by 186
Medical therapies for meningiomas
Wen, P. Y., Quant, E., Drappatz, J., Beroukhim, R., & Norden, A. D. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0349-8 · Cited by 181
Self-citationWen, P. Y., Yung, W. K. A., Lamborn, K. R., Norden, A. D., Cloughesy, T. F., Abrey, L. E., Fine, H. A., Chang, S. M., Robins, H. I., Fink, K., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-010 · Cited by 162
Self-citationSalvage chemotherapy With CPT-11 for recurrent meningioma
Chamberlain, M. C., Tsao-Wei, D. D., & Groshen, S. G. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9093-x · Cited by 109
Platelet-derived growth factor expression and stimulation in human meningiomas
Black, P. M., Carroll, R. S., Głowacka, D., Riley, K. N., & Dashner, K. (1994) · Journal of neurosurgery · doi:10.3171/jns.1994.81.3.0388 · Cited by 101
Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma
Chamberlain, M. C. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0741-z · Cited by 96
Advances in meningioma therapy
Norden, A. D., Drappatz, J., & Wen, P. Y. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0034-5 · Cited by 95
Self-citationPhase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma
Reardon, D. A., Norden, A. D., Desjardins, A., Vredenburgh, J. J., Herndon, J. E., Sykes, A. D., Sampson, J. H., Gururangan, S., Peters, K. B., McLendon, R. E., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0687-1 · Cited by 92
Self-citationYang, S., & Xu, G. (2001) · Journal of Clinical Neuroscience · doi:10.1054/jocn.2001.0877 · Cited by 77
Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor
Todo, T., Adams, E. F., Fahlbusch, R., Dingermann, T., & Werner, H. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.84.5.0852 · Cited by 72
Raizer, J. J., Abrey, L. E., Lassman, A. B., Chang, S., Lamborn, K. R., Kuhn, J. G., Yung, W. K. A., Gilbert, M. R., Aldape, K., Wen, P. Y., et al. (2009) · Neuro-Oncology · doi:10.1093/neuonc/nop017 · Cited by 56
Self-citation
Cited by
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review
Schaff, L. R., & Mellinghoff, I. K. (2023) · JAMA · doi:10.1001/jama.2023.0023 · Cited by 1,271
EANO guidelines for the diagnosis and treatment of meningiomas
Goldbrunner, R., Minniti, G., Preusser, M., Jenkinson, M. D., Sallabanda, K., Houdart, E., von Deimling, A., Stavrinou, P., Lefranc, F., Lund-Johansen, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30321-7 · Cited by 854
Sahm, F., Schrimpf, D., Stichel, D., Jones, D. T. W., Hielscher, T., Schefzyk, S., Okonechnikov, K., Koelsche, C., Reuss, D. E., Capper, D., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30155-9 · Cited by 852
EANO guideline on the diagnosis and management of meningiomas
Goldbrunner, R., Stavrinou, P., Jenkinson, M. D., Sahm, F., Mawrin, C., Weber, D. C., Preusser, M., Minniti, G., Lund-Johansen, M., Lefranc, F., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab150 · Cited by 742
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma
Abedalthagafi, M., Bi, W. L., Aizer, A. A., Merrill, P. H., Brewster, R., Agarwalla, P. K., Listewnik, M. L., Dias-Santagata, D., Thorner, A. R., Van Hummelen, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov316 · Cited by 293
Self-citation
Metadata
- Authors
- Kaley, T. J., Wen, P., Schiff, D., Ligon, K., Haidar, S., Karimi, S., Lassman, A. B., Nolan, C. P., DeAngelis, L. M., Gavrilovic, I., Norden, A., Drappatz, J., Lee, E. Q., Purow, B., Plotkin, S. R., Batchelor, T., Abrey, L. E., & Omuro, A.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-08-06
- Volume
- 17
- Issue
- 1
- Pages
- 116-121
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W1995312162
- Cited by
- 294
- References
- 24
- FWCI
- 13.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.